1,043
Participants
Start Date
September 24, 2018
Primary Completion Date
January 30, 2020
Study Completion Date
February 15, 2020
cefepime/AAI101 combination
cefepime 2 g / AAI101 500 mg
Piperacillin/tazobactam
piperacillin 4 GM / tazobactam 500 MG
MHAT Rahila Angelova AD, Pernik, Pernik
Bugat Pal Korhaz, Gyöngyös
Unimed Adjara - Kutaisi oncological centre, Kutaisi
Clinical Projects Research, Worcester
Hospital del Mar, Department of Infectious Disease, Barcelona
"University Hospital for Infectious Diseases Dr. Fran Mihaljevic Department for general infectious diseases", Zagreb
Clinical Hospital Center Zvezdara, Belgrade
Chernihiv City Hospital #2 of Chernihiv City Council, department of Urology, Chernihiv
Clinica Internacional - Sede San Borja, Lima
Florida Urology Partners, Tampa
Tartu University Hospital, Tartu
Mercury Street Medical, Butte
Washington University School of Medicine, St Louis
Republican Siauliai caunty hospital, Šiauliai
University of New Mexico Health Sciences Center, Albuquerque
Interne oddelenie, Nemocnica Malacky, Nemocnicna a.s., Malacky
Southbay Pharma Research, Buena Park
St. Josephs Clinical Research, Anaheim
Scientific Research Center Eco-Safety, Saint Petersburg
Brest Regional Hospital, Brest
HIGA Dr Ramon Carrillo, Buenos Aires
Uroklinika, LLC, Riga
Centro Especializado en Investigación Clínica S.C., Boca del Río
Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Klinika Chorob Wewnetrznych, Nefrologii i Transplantologii, Warsaw
Lead Sponsor
Collaborators (1)
Medpace, Inc.
INDUSTRY
Allecra
INDUSTRY